

Technology/ Title	DBPR117: A Precision Medicine (mAb) Targeting RSPO3/Wnt-Mediated Tumorigenesis	
Technology Type	<input type="checkbox"/> Biotechnology	<input type="checkbox"/> Device/Diagnostics
	<input checked="" type="checkbox"/> Pharmaceutical	<input type="checkbox"/> Others:_____ -
Contact Person	Name: Po-Hsuan Sung	Title: Project Manager
	Telephone(work): +886-37-246-166 ext. 35702	Mobile: N/A
	Email: phsung@nhri.org.tw	
Link	http://ibpr.nhri.org.tw/zhtw/wp-content/uploads/2018/07/New-2018_NCR-of-DBPR117.pdf	
Technology Description	R-spondin 3 (RSPO3) was identified as a novel key modulator of cancer development and a potential target for treatment of cancers. Therefore, we selected RSPO3 as a therapeutic target and discovered a potent neutralizing antibody, DBPR117, that was shown to have anti-cancer activity. DBPR117 is a humanized IgG1 that is capable of neutralizing the aberration of RSPO3-mediated Wnt/ β -catenin signaling. DBPR117 is comparable with rosmantuzumab (131R010), an antibody developed by OncoMed, as shown in a number of assays including binding assays, <i>in vitro</i> ligand neutralization and wound healing assays, and <i>in vivo</i> PDX (patient-derived xenograft) or CDX (cell line-derived xenograft) models.	

Intellectual Property	2018: PCT and ROC Patent entitled Anti-RSPO3 antibodies, compositions, methods and uses.
Key Publications	N/A
Business Opportunity	DBPR117 can inhibit cancer stemness and DBPR117 will be examined for activity in reducing RSPO3-mediated tumorigenesis and metastasis. DBPR117 will be developed to cover a wide range of cancers along with companion diagnostics that can identify patients who are most likely to benefit from DBPR117, alone or in combination with other agents.